Seminars in Nuclear Medicine
Volume 36, Issue 1 , Pages 73-92 , January 2006

The Role of Fluorodeoxyglucose, 18F-Dihydroxyphenylalanine, 18F-Choline, and 18F-Fluoride in Bone Imaging with Emphasis on Prostate and Breast

  • Werner Langsteger, MD (FACE)

      Affiliations

    • PET–CT Center Linz, Department of Nuclear Medicine and Endocrinology, St. Vincent’s Hospital, Linz, Austria.
    • Corresponding Author InformationAddress reprint requests to Werner Langsteger, MD, PET–CT Center Linz, Department of Nuclear Medicine and Endocrinology, St. Vincent’s Hospital, Seilerstaette 4, A-4020, Linz, Austria.
    • ,
  • Martin Heinisch, MD

      Affiliations

    • PET–CT Center Linz, Department of Nuclear Medicine and Endocrinology, St. Vincent’s Hospital, Linz, Austria.
    • ,
  • Ignac Fogelman, BSc, MD (FRCP)

      Affiliations

    • Division of Imaging, King’s College, London, UK.

References 

  1. Cook GJR , Fogelman I . The role of positron emission tomography in the management of bone metastases . Cancer Suppl . 2000;88:2927–2933
  2. Valk PE , Pounds TR , Tesar RD , et al.   Cost-effectiveness of PET imaging in clinical oncology . Nucl Med Biol . 1996;23:737–743
  3. Gambhir SS , Shepherd JE , Shah BD , et al.   Analytical decision model for the cost-effective management of solitary pulmonary nodules . J Clin Oncol . 1998;16:2113–2122
  4. Even-Sapir E , Metser U , Flusser G , et al.   Assessment of malignant skeletal disease (Initial experience with 18 F–fluoride PET/CT and Comparison between 18F–fluoride PET and 18F–fluoride PET/CT) . J Nucl Med . 2004;45:272–278
  5. Fogelman I , Cook G , Israel O , et al.   Positron emission tomography and bone metastases . Semin Nucl Med . 2005;35:135–142
  6. Minn H , Clavo AC , Wahl RL . Influence of hypoxia on tracer accumulation in squamous cell carcinoma (In vitro evaluation for PET imaging) . Nucl Med Biol . 1996;23:941–946
  7. Petren-Mallmin M , Andreasson I , Ljunggren O , et al.   Skeletal metastases from breast cancer (Uptake of 18F-fluoride measured with positron emission tomography in correlation with CT) . Skel Radiol . 1998;27:72–76
  8. Hoegerle S , Altehoefer C , Ghanem N , et al.   18F–DOPA positron emission tomography for tumor detection in patients with medullary thyroid carcinoma and elevated calcitonin levels . Eur J Nucl Med . 2001;28:64–71
  9. Mundy GR . Metastasis to bone (Causes, consequences and therapeutic opportunities) . Nat Rev Cancer . 2002;2:584–593
  10. Kahn D , Weiner GJ , Ben-Haim S , et al.   Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults . Blood . 1994;83:958–963
  11. Jacobson AF . Bone scanning in metastatic disease . In:  Collier BD ,  Fogelman I ,  Rosenthall L editor. Skeletal Nuclear Medicine . St Louis: Mosby; 1996;p. 87–123
  12. O’Mara R . Skeletal scanning in neoplastic disease . Cancer . 1976;37:480–486
  13. Horiuchi-Suzuki K , Saji H , Ohta H . What is the source of the skeletal affinity of 99mTC-V-DMSA? . Eur J Nucl Med Mol Imaging . 2004;31:1675–1676
  14. Cook GJ , Fogelman I . The role of nuclear medicine in monitoring treatment in skeletal malignancy . Semin Nucl Med . 2001;31:206–211
  15. Koizumi M , Matsumoto S , Takahashi S , et al.   Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer . Clin Nucl Med . 1999;24:15–20
  16. Schirrmeister H, Guhlmann A, Elsner K, et al: Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus 18F PET. J Nucl Med 40:1623-1629
  17. Bury T , Barreto A , Daenen F , et al.   Flourine-18 deoxyglucose positron emission tomography for the detection of bone mestastases in patients with non-small cell lung cancer . Eur J Nucl Med . 1998;25:1244–1247
  18. Schaner EG , Chang AE , Doppman JL , et al.   Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules (A prospective radiologic–pathologic study) . Am J Roentgenol . 1978;131:51–54
  19. Vanel D , Henry-Amar M , Lumbroso J , et al.   Pulmonary evaluation of patients with osteosarcoma (Roles of standard radiography, tomography, CT, scintigraphy, and tomoscintigraphy) . Am J Roentgenol . 1984;143:519–523
  20. Muhm JR , Brown LR , Crowe JK , et al.   Comparison of whole lung tomography and computed tomography for detecting pulmonary nodules . Am J Roentgenol . 1978;131:981–984
  21. Alavi A , Kung JW , Zhuang H . Implications of PET based molecular imaging on the current and future practice of medicine . Semin Nucl Med . 2004;34:56–69
  22. Crim JR , Cracchiolo A , Bassett LW , et al.   Magnetic resonance imaging of the hindfoot . Foot Ankle . 1989;10:1–7
  23. Hilpert PL , Friedman AC , Radecki PD , et al.   MRI of hemorrhagic renal cysts in polycystic kidney disease . Am J Roentgenol . 1986;146:1167–1172
  24. Semelka RC , Bagley AS , Brown ED , et al.   Solitary hepatic metastasis (Comparison of dynamic contrast-enhanced CT and MR imaging with fat-suppressed T2-weighted, breathhold T1-weighted FLASH, and dynamic gadolinium-enhanced FLASH sequences) . J Magn Reson Imaging . 1994;4:319–323
  25. Stark DD , Wittenberg J , Butch RJ , et al.   Hepatic metastases (Randomized, controlled comparison of detection with MR imaging and CT) . Radiology . 1987;165:399–406
  26. Haubold-Reuter BG , Duewell S , Schilcher BR , et al.   The value of bone scintigraphy, bone marrow scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumors (A prospective study) . Eur J Nucl Med . 1993;20:1063–1069
  27. Kosuda S , Tatsumi K , Hisaaki Y , et al.   Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI . J Nucl Med . 1996;37:975–978
  28. Athanasoulis T , Koutsikos J , Zerva C . What is the source of the skeletal affinity of 99mTC-V-DMSA? . Eur J Nucl Med Mol Imaging . 2004;31:1673–1674
  29. Smoker WRK , Goderski JC , Knutzon RK , et al.   The role of MR imaging in evaluating metastatic spinal disease . Am J Roentgenol . 1987;149:1241–1248
  30. Frank JA , Ling A , Patronas NJ , et al.   Detection of malignant bone tumors (MR imaging vs scintigraphy) . Am J Roentgenol . 1990;55:1043–1048
  31. Steinborn MM , Heuck AF , Tiling R , et al.   Wholebody bone marrow MRI in patients with metastatic disease to the skeletal system . J Comput Assist Tomogr . 1999;23:123–129
  32. Calautti C , Baron JC . Functional neuroimaging studies of motor recovery after stroke in adults (A review) . Stroke . 2003;34:1553–1566
  33. Grenier N , Basseau F , Ries M , et al.   Functional MRI of the kidney . Abdom Imaging . 2003;28:164–175
  34. Hetzel M , Hetzel J , Arslandemir C , et al.   Reliability of symptoms to determine use of bone scans to identify bone metastases in lung cancer (Prospective study) . Br Med J . 2004;328:1051–1052
  35. Schirrmeister H , Arslandemir C , Glattnig G , et al.   Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer . Eur J Nucl Med Mol Imaging . 2004;31:964–968
  36. Savelli G , Maffioli L , Maccauro M , et al.   Bone scintigraphy and added value of SPECT (single photon emission tomography) in detecting skeletal lesions . Q J Nucl Med . 2001;45:27–37
  37. Roland J , van den Weygaert D , Krug B , et al.   Metastases seen on SPECT imaging despite a normal planar bone scan . Clin Nucl Med . 1995;20:1052–1054
  38. Sedonja I , Budihna NV . The benefit of SPECT when added to planar scintigraphy in patients with bone metastases in the spine . Clin Nucl Med . 1999;24:407–413
  39. Schirrmeister H , Glattnig G , Hetzel J , et al.   Prospective evaluation of the clinical value of planar bone scans, SPECT, and 18F-labeled NaF PET in newly diagnosed lung cancer . J Nucl Med . 2001;42:1800–1804
  40. Warburg O . On the origin of cancer cells . Science . 1954;123:306–314
  41. Aoki J , Watanabe H , Shinozaki T , et al.   FDG PET of primary benign and malignant bone tumors (Standardized uptake value in 52 lesions) . Radiology . 2001;219:774–777
  42. Cook GJ , Houston S , Rubens R , et al.   Detection of bone metastases in breast cancer by 18FDG PET (Differing metabolic activity in osteoblastic and osteolytic lesions) . J Clin Oncol . 1998;16:3375–3379
  43. Galasko CSB . Skeletal Metastases . London: Butterworths; 1986;
  44. Paquet N , Albert A , Foidart J , et al.   Within-patient variability of 18F-FDG (Standardized uptake values in normal tissues) . J Nucl Med . 2004;45:784–788
  45. Keyes JW . SUV (Standard uptake or silly useless value?) . J Nucl Med . 1995;36:1836–1839
  46. Ramos CD , Erdi YE , Gonen M , et al.   18F-FDG PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection . Eur J Nucl Med . 2001;28:155–164
  47. Schulte M , Brecht-Krauss D , Werner M , et al.   Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET . J Nucl Med . 1999;40:1637–1643
  48. Franzius C , Bielack S , Flege S , et al.   Prognostic significance of (18) F-FDG and (99m) Tc methylene diphosphonate uptake in primary osteosarcoma . J Nucl Med . 2002;43:1012–1017
  49. Brenner W , Vernon C , Muzi M , et al.   Comparison of different quantitative approaches to 18F-fluoride PET scans . J Nucl Med . 2004;45:1493–1500
  50. Blau M , Nagler W , Bender MA . Fluorine-18 (A new isotope for bone scanning) . J Nucl Med . 1962;3:332–334
  51. Blau M , Ganatra R , Bender MA . 18F-Fluoride for bone imaging . Semin Nucl Med . 1972;2:31–37
  52. Narita N , Kato K , Nakagaki H , et al.   Distribution of fluoride concentration in the rat’s bone . Calcif Tissue Int . 1990;46:200–204
  53. Ishiguro K , Nakagaki H , Tsuboi S , et al.   Distribution of fluoride in cortical bone of human rib . Calcif Tissue Int . 1993;52:278–282
  54. Wootton R , Dore C . The single-passage extraction of 18F in rabbit bone . Clin Physiol Meas . 1986;7:333–343
  55. Schirrmeister H , Rentschler M , Kotzerke  , et al.   Darstellung des normalen Skelettsystems mit 18F Na-PET im Vergleich zur konventionellen Skelettszintigraphie mit 99mTc-MDP . Fortschr Röntgenstr . 1998;168(5):451–456
  56. Hawkins RA , Choi Y , Huang SC , et al.   Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET . J Nucl Med . 1992;33:633–642
  57. Wolfenden JM , Pitt MJ , Durie BGW , et al.   Comparison of bone scintigraphy and radiology in myeloma . Radiology . 1980;134:723–728
  58. Fogelman I . Skeletal uptake of diphosphonate (A review) . Eur J Nucl Med . 1980;5:473–476
  59. Hoh CK , Hawkins RA , Dahlbom M , et al.   Whole body skeletal imaging with (18F) fluoride ion and PET . J Comput Assist Tomogr . 1993;17:34–41
  60. Cook GJR , Fogelman I . The role of positron emission tomography in skeletal disease . Semin Nucl Med . 2001;31:50–61
  61. Hoegerle S , Juengling F , Otte A , et al.   Combined FDG and (F-18) fluoride whole-body PET (A feasible two-in-one approach to cancer imaging?) . Radiology . 1998;209:253–258
  62. Schirrmeister H, Guhlmann A, Kotzerke J, et al: Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 17:2381-2389
  63. Hetzel M , Arslandemir C , Konig HH , et al.   F-18 NaF PET for detection of bone metastases in lung cancer (Accuracy, cost-effectiveness, and impact on patient management) . J Bone Miner Res . 2003;18:2206–2214
  64. Kaltsas G , Rockall A , Papagodias D , et al.   Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumors . Eur J Endocrinol . 2004;151:15–27
  65. Eriksson B , Bergstrom M , Sundin A , et al.   The role of PET in localization of neuroendocrine and adrenocortical tumors . Ann NY Acad Sci . 2002;970:159–169
  66. Bombardieri E , Seregni E , Vallano C , et al.   Positron of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors . J Nucl Med Mol Imag . 2004;48:150–163
  67. Eriksson B , Orefors H , Oberg K , et al.   Developments in PET for the detection of endocrine tumors . Best Pract Res Clin Endocrinol Metab . 2005;19:311–324
  68. Sundin A , Eriksson B , Bergstrom M , et al.   PET in the diagnosis of neuroendocrine tumors . Ann N Y Acad Sci . 2004;1014:246–257
  69. Li S , Beheshti M . The radionuclide molecular imaging and therapy of neuroendocrine tumors . Curr Cancer Drug Targets . 2005;2:139–148
  70. Moul JW . Prostate specific antigen only progression of prostate cancer . J Urol . 2000;163:1632–1642
  71. Huch Boni RA , Meyenberger C , Pok Lundquist J , et al.   Value of endorectal coil versus body coil MRI for diagnosis of recurrent pelvic malignancies . Abdom Imaging . 1996;21:345–352
  72. Leventis AK , Shariat SF , Slawin KM . Local recurrence after radical prostatectomy (Correlation of US features with prostatic fossa biopsy findings) . Radiology . 2001;219:432–439
  73. Roudier MP , Vesselle H , True LD , et al.   Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer (The effect of bisphosphonate therapy on bone scintigraphy results) . Clin Exp Metastasis . 2003;20:171–180
  74. Roehl KA , Han M , Ramos CG , et al.   Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients (Long-term results) . J Urol . 2004;172:910–914
  75. Kamat AM , Rosser CJ , Levy LB , et al.   Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure . Urology . 2004;63:1132–1137
  76. Partin AW , Pearson JD , Landis PK , et al.   Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases . Urology . 1994;43:649–659
  77. Okotie OT , Aronson WJ , Wieder JA , et al.   Predictors of metastatic disease in men with biochemical failure following radical prostatectomy . J Urol . 2004;171:2260–2264
  78. Hermann K , Schöder H , Eberhard S , et al.   FDG PET for the detection of recurrent/metastatic prostate carcinoma in patients with rising PSA after radical prostatectomy . J Nucl Med . 2004;45:359
  79. Fricke E , Machtens S , Hofmann M , et al.   Positron emission tomography with (11) C-acetate and (18) F-FDG in prostate cancer patients . Eur J Nucl Med Mol Imaging . 2003;30:607–611
  80. Larson SM , Morris M , Gunther I , et al.   Tumor localization of 16 beta-(18)F- fluoro-5α-dihydrotestosterone versus (18)F-FDG in patients with progressive, metastatic prostate cancer . J Nucl Med . 2004;45:366–373
  81. Morris MJ , Akhurst T , Osman I , et al.   Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer . Urology . 2002;59:913–918
  82. Nunez R , Macapinlac HA , Yeung HW , et al.   Combined 18 F-FDG and 11 C-methionine PET scans in patients with newly progressive metastatic prostate cancer . J Nucl Med . 2002;43:46–55
  83. Hara T , Kosaka N , Shinora N , et al.   PET imaging of brain tumor with (methyl-11C) choline . J Nucl Med . 1997;38:842–847
  84. Hara T , Yuasa M . Automated synthesis of fluoroine-18 labeled choline analogue (2-Fluoroethyol-dimethyl-2-oxytheylammonium) . J Nucl Med . 1997;38:44
  85. DeGrado TR , Coleman RE , Wang S , et al.   Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography (Initial findings in prostate cancer) . Cancer Res . 2001;61:110–117
  86. DeGrado TR , Baldwin SW , Wang S , et al.   Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers . J Nucl Med . 2001;42:1805–1814
  87. Macara IG . Elevated phosphocholine concentration in ras-transformed NIH 3T3 cells arises from increased choline kinase activity, not from phosphatidylcholine breakdown . Mol Cell Biol . 1989;9:325–328
  88. Heinisch M , Meier S , Salomon U , et al.   Initial experience in F18-fluorocholine PET/CT in prostate cancer (Implications for the determination of a PET/CT acquisition protocol) . Q J Nucl Med Mol Imaging . 2004;48:7
  89. Langsteger W , Heinisch M , Janetschek G , et al.   Diagnosis of prostate cancer with FCH positron emission tomography/computed tomography (First results) . Mol Imaging Biol . 2005;7:113–114
  90. Jemal A , Tiwari RC , Murray T , et al.   Cancer statistics, 2004 . CA Cancer J Clin . 2004;54:8–29
  91. Partin AW , Kattan MW , Subong EN , et al.   Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer (A multi-institutional update) . JAMA . 1997;277:1445–1451
  92. Kattan MW , Wheeler TM , Scardino PT . Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer . J Clin Oncol . 1999;17:1499–1507
  93. Kattan MW , Eastham JA , Stapleton AM , et al.   A preoperative nomogram for disease reccurrence following radical prostatectomy for prostate cancer . J Natl Cancer Inst . 1998;90:766–771
  94. D’Amico AV , Whittington R , Schnall M , et al.   The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer . Cancer . 1995;75:2368–2372
  95. Charhon SA , Chapuy MC , Delvin EE , et al.   Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia . Cancer . 1983;15:918–924
  96. Chybowski FM , Keller JJ , Bergstralh EJ , et al.   Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer (Prostate specific antigen is superior to all other clinical parameters) . J Urol . 1991;145:313–318
  97. Lee CT , Oesterling JE . Using prostate-specific antigen to eliminate the staging radionuclide bone scan . Urol Clin North Am . 1997;24:389–394
  98. Cher ML , Bianco FJ , Lam JS , et al.   Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radial prostatectomy . J Urol . 1998;160:1387–1391
  99. Kane CJ , Amling Cl , Johnstone PA , et al.   Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy . Urology . 2003;61:607–611
  100. Ornstein DK , Colberg JW , Virgo KS , et al.   Evaluation and management of men whose radical prostatectomies failed (Results of international survey) . Urology . 1998;52:1047–1054
  101. Langsteger W , Heinisch M , Janetschek G , et al.   18F Choline PET/CT in preoperative staging of prostate cancer . Nuklearmedizin . 2005;44:36
  102. de Jong IJ , Pruim J , Elsinga PH , et al.   11C-Choline positron emission tomography for the evaluation after treatment of localized prostate cancer . Eur Urol . 2003;44:32–38
  103. Heinisch M, Dirisamer A, Loidl W, et al: PET/CT with F-18-fluorocholine for restaging of prostate cancer patients: Meaningful at PSA < 5 ng/ml? Mol Imaging Biol (in press)
  104. Coleman R , DeGrado T , Wang S , et al.   Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent . Clin Positron Imaging . 2000;3:147
  105. Shreve PD , Grossman HB , Gross MD , et al.   Metastatic prostate cancer (Initial findings of PET with 2-deoxy-2-(F-18) fluoro-d-glucose) . Radiology . 1996;199:751–756
  106. Coleman RE , Seaman JJ . The role of zoledronic acid in cancer (Clinical studies in the treatment and prevention of bone metastases) . Semin Oncol . 2001;28:11–16
  107. Guise Ta , Yin JJ , Taylor SD , et al.   Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis . J Clin Invest . 1996;98:1544–1549
  108. Shen X , Falzon M . PTH-related protein modulated PC-3 prostate cancer cell adhesion and integrin subunit profile . Mol Cell Endocrinol . 2003;199:165–177
  109. Moon DH , Maddahi J , Silverman DH , et al.   Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent of metastatic breast carcinoma . J Nucl Med . 1998;39:431–435
  110. Wahl RL , Cody RL , Hutchins GD , et al.   Primary and metastatic breast carcinoma (Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-(F-18)-fluoro-2-deoxy-d-glucose) . Radiology . 1991;179:765–770
  111. Lonneux M , Borbath II , Berliere M , et al.   The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer . Clin Positron Imaging . 2000;3:45–49
  112. Ohta M , Tokuda Y , Suzuki Y , et al.   Whole body PET for the evaluation of bony metastases in patients with breast cancer (Comparison with 99Tcm-MDP bone scintigraphy) . Nucl Med Commun . 2001;22:875–879
  113. Yang SN , Liang JA , Lin FJ , et al.   Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer . J Cancer Res Clin Oncol . 2002;128:325–328
  114. Stafford SE , Gralow JR , Schubert EK , et al.   Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy . Acad Radiol . 2002;9:913–921
  115. Tritz DB , Doll DC , Ringenberg QS , et al.   Bone marrow involvement in small cell lung cancer (Clinical significance and correlation with routine laboratory variables) . Cancer . 1989;63:763–766
  116. Bezwoda WR , Lewis D , Livini N . Bone marrow involvement in anaplastic small cell lung cancer (Diagnosis, hematologic features, and prognostic implications) . Cancer . 1986;58:1762–1765
  117. Trillet V , Revel D , Combaret V , et al.   Bone marrow metastases in small cell lung cancer (Detection with magnetic resonance imaging and monoclonal antibodies) . Br J Cancer . 1989;60:83–88
  118. Marom EM , McAdams HP , Erasmus JJ , et al.   Staging non-small cell lung cancer with whole-body PET . Radiology . 1999;212:803–809
  119. Jadvar H , Gamie S , Ramanna L , et al.   Musculoskeletal system . Semin Nucl Med . 2004;34:254–261
  120. Tse N , Hoh C , Hawkins R , et al.   Positron emission tomography diagnosis of pulmonary metastases in osteogenic sarcoma . Am J Clin Oncol . 1994;17:22–25
  121. Franzius C , Daldrup-Link HE , Sciuk J , et al.   FDG-PET for detection of pulmonary metastases from malignant primary bone tumors (Comparison with spiral CT) . Ann Oncol . 2001;12:479–586
  122. Gayed I , Vu T , Johnson M , et al.   Comparison of bone and 2-deoxy-2-(18F) fluoro-d-glucose positron emission tomography in the evaluation of bony metastases in lung cancer . Mol Imaging Biol . 2003;5:26–31
  123. Al-Sugair A , Coleman R . Relative diagnostic efficiency of F-18 FDG PET and bone scintigraphy for detection of osseous metastases in primary or secondary lung cancer . J Nucl Med . 1999;40:20
  124. Garcia JR , Simo M , Perez G , et al.   99m Tc-MDP bone scintigraphy and 18F FDG positron emission tomography in lung and prostate cancer patients (Different affinity between lytic and sclerotic bone metastases) . Eur J Nucl Med Mol Imaging . 2003;30:1714
  125. Lin JD , Huang MJ , Juang JH , et al.   Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases . Thyroid . 1999;9:1227–1235
  126. Schirrmeister H , Buck A , Guhlmann A , et al.   Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 Sodium Fluoride positron emission tomography . Thyroid . 2001;11:677–683
  127. Langsteger W . 18 F DOPA PET vs 18 FDG PET in the follow up of MTC patients (Comparison and first results) . Mol Imaging Biol . 2004;6:87
  128. Langsteger W , Meier S , Heinisch M , et al.   Comparison and first results of 18 F DOPA versus FDG PET in the follow up of MTC patients . Q J Nucl Med Mol Imaging . 2004;48:6
  129. Moog F , Kotzerke J , Reske SN . FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma . J Nucl Med . 1999;40:1407–1413
  130. Leonard RC , Owen JP , Proctor SJ , et al.   Multiple myeloma (Radiology or bone scanning?) . Clin Radiol . 1981;32:291–295
  131. Aoki J , Inoue T , Tomiyoshi K , et al.   Nuclear imaging of bone tumors (FDG-PET) . Semin Musculoskelet Radiol . 2001;5:183–187
  132. Brenner W , Bohuslavizki KH , Eary JF . PET imaging of osteosarcoma . J Nucl Med . 2003;44:930–942

PII: S0001-2998(05)00056-5

doi: 10.1053/j.semnuclmed.2005.09.002

Seminars in Nuclear Medicine
Volume 36, Issue 1 , Pages 73-92 , January 2006

Article Tools

* Image Usage & Resolution